128 related articles for article (PubMed ID: 8844103)
21. Myelodysplastic syndromes: immunohistochemical and morphometric evaluation of proliferative activity in erythropoiesis and endoreduplicative capacity of megakaryocytes.
Thiele J; Hoffmann I; Bertsch HP; Fischer R
Virchows Arch A Pathol Anat Histopathol; 1993; 423(1):33-8. PubMed ID: 8105604
[TBL] [Abstract][Full Text] [Related]
22. Fluorescence in-situ hybridization (FISH) reveals that in chronic myelogenous leukaemia (CML) following interferon-alpha therapy, normalization of megakaryocyte size is associated with the loss of bcr/abl translocation.
Thiele J; Schmitz B; Gross H; Kvasnicka HM; Niederle N; Leder LD; Fischer R
Histopathology; 1997 Sep; 31(3):215-21. PubMed ID: 9354890
[TBL] [Abstract][Full Text] [Related]
23. Increased IFN-gamma synthesis by T cells from patients on imatinib therapy for chronic myeloid leukemia.
Aswald JM; Lipton JH; Aswald S; Messner HA
Cytokines Cell Mol Ther; 2002; 7(4):143-9. PubMed ID: 14660054
[TBL] [Abstract][Full Text] [Related]
24. [Comparative efficiency of conventional myelosuppressive chemotherapy and therapy including interferon alpha in patients with chronic myeloid leukemia].
Volkova SA; Prytkova MV; Borovkov NN
Klin Med (Mosk); 2004; 82(3):45-50. PubMed ID: 15114775
[TBL] [Abstract][Full Text] [Related]
25. [Prediction of interferon therapy efficacy in chronic myeloid leukemia according to data of histomorphological study].
Khoroshko ND; Turkina AG; Kumas SM; Zhuravlev VS; Kuznetsov SV; Sokolova MA; Semenova EA; Kaplanskaia IB; Frank GA; Korolev AV; Shcherbinina LA; Zakharova AV; Domracheva EV; Zingerman BA
Ter Arkh; 2004; 76(7):44-50. PubMed ID: 15379127
[TBL] [Abstract][Full Text] [Related]
26. Bone marrow changes in chronic myelogenous leukaemia after long-term treatment with the tyrosine kinase inhibitor STI571: an immunohistochemical study on 75 patients.
Thiele J; Kvasnicka HM; Schmitt-Graeff A; Kriener S; Engels K; Staib P; Ollig ES; Keller C; Fokkema S; Griesshammer M; Waller CF; Ottmann OG; Hansmann ML
Histopathology; 2005 May; 46(5):540-50. PubMed ID: 15842636
[TBL] [Abstract][Full Text] [Related]
27. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results.
Kantarjian HM; Talpaz M; O'Brien S; Smith TL; Giles FJ; Faderl S; Thomas DA; Garcia-Manero G; Issa JP; Andreeff M; Kornblau SM; Koller C; Beran M; Keating M; Rios MB; Shan J; Resta D; Capdeville R; Hayes K; Albitar M; Freireich EJ; Cortes JE
Clin Cancer Res; 2002 Jul; 8(7):2177-87. PubMed ID: 12114418
[TBL] [Abstract][Full Text] [Related]
28. Ki-S1 and PCNA expression in erythroid precursors and megakaryocytes--a comparative study on proliferative and endoreduplicative activity in reactive and neoplastic bone marrow lesions.
Thiele J; Bertsch HP; Kracht LW; Anwander T; Zimmer JD; Kreipe H; Fischer R
J Pathol; 1994 May; 173(1):5-12. PubMed ID: 7523642
[TBL] [Abstract][Full Text] [Related]
29. Intracellular cytokine analysis of interferon-gamma in T cells of patients with chronic myeloid leukemia.
Aswald JM; Lipton JH; Messner HA
Cytokines Cell Mol Ther; 2002 Dec; 7(2):75-82. PubMed ID: 12607798
[TBL] [Abstract][Full Text] [Related]
30. Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase.
O'Brien S; Giles F; Talpaz M; Cortes J; Rios MB; Shan J; Thomas D; Andreeff M; Kornblau S; Faderl S; Garcia-Manero G; White K; Mallard S; Freireich E; Kantarjian HM
Cancer; 2003 Sep; 98(5):888-93. PubMed ID: 12942553
[TBL] [Abstract][Full Text] [Related]
31. [Histologic and hematological findings in CML. A comparative immunohistochemical-morphometric and clinical study on bone marrow biopsies from 604 patients derived from two institutes of pathology (Cologne/Freiburg)].
Thiele J; Kvasnicka HM; Schmitt-Graeff A; Schaefer HE
Pathologe; 2000 Jan; 21(1):39-54. PubMed ID: 10663668
[TBL] [Abstract][Full Text] [Related]
32. Prolonged chronic phase in chronic myelogenous leukemia after homoharringtonine therapy.
Li YF; Deng ZK; Xuan HB; Zhu JB; Ding BH; Liu XN; Chen BA
Chin Med J (Engl); 2009 Jun; 122(12):1413-7. PubMed ID: 19567163
[TBL] [Abstract][Full Text] [Related]
33. Interferon alpha in the treatment of chronic myelogenous leukemia.
Robak T
Arch Immunol Ther Exp (Warsz); 1998; 46(6):347-53. PubMed ID: 9883313
[TBL] [Abstract][Full Text] [Related]
34. Endomitotic index of megakaryocytes measured by flow cytometry helps to diagnose hematological disorders with abnormal platelet counts.
Baatout S; Chatelain B; Staquet P; Symann M; Chatelain C
Anticancer Res; 1998; 18(5A):3347-53. PubMed ID: 9858907
[TBL] [Abstract][Full Text] [Related]
35. Human megakaryocyte polyploidization is associated with a decrease in GPIIIA expression.
Baatout S; Chatelain B; Staquet P; Symann M; Chatelain C
Anticancer Res; 1999; 19(6B):5187-9. PubMed ID: 10697532
[TBL] [Abstract][Full Text] [Related]
36. Bone marrow trephine biopsy findings in chronic myeloid leukemia.
Khonglah Y; Basu D; Dutta TK
Malays J Pathol; 2002 Jun; 24(1):37-43. PubMed ID: 16329554
[TBL] [Abstract][Full Text] [Related]
37. [A trial for prolongation of chronic phase of chronic myeloid leukemia--maintenance of leukocyte counts within normal range with busulfan].
Matsuo T; Tomonaga M; Kuriyama K; Jinnai I; Jubashi T; Nonaka H; Kohno T; Tsukasaki K; Atogami S; Itoyama T
Rinsho Ketsueki; 1989 May; 30(5):625-30. PubMed ID: 2795875
[TBL] [Abstract][Full Text] [Related]
38. Effective and safe interferon treatment for Japanese patients with chronic myelogenous leukemia relapse after bone marrow transplantation. The Nagoya Blood and Marrow Transplantation Group.
Sao H; Kato C; Kitaori K; Adachi T; Yano K; Kobayashi M; Kojima H; Tanimoto M; Hirabayashi N; Minami S; Yamada H; Morishita GY; Morishima Y; Kodera Y
Int J Hematol; 2000 Aug; 72(2):237-42. PubMed ID: 11039675
[TBL] [Abstract][Full Text] [Related]
39. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.
Posthuma EF; Marijt EW; Barge RM; van Soest RA; Baas IO; Starrenburg CW; van Zelderen-Bhola SL; Fibbe WE; Smit WM; Willemze R; Falkenburg JH
Biol Blood Marrow Transplant; 2004 Mar; 10(3):204-12. PubMed ID: 14993886
[TBL] [Abstract][Full Text] [Related]
40. Marrow fibrosis, indicator of therapy failure in chronic myeloid leukemia - prospective long-term results from a randomized-controlled trial.
Buesche G; Hehlmann R; Hecker H; Heimpel H; Heinze B; Schmeil A; Pfirrmann M; Gomez G; Tobler A; Herrmann H; Kappler M; Hasford J; Buhr T; Kreipe HH; Georgii A
Leukemia; 2003 Dec; 17(12):2444-53. PubMed ID: 14562117
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
